The information presented in this Advisory is intended as general information of interest to physicians and other health care professionals. The recommendations and advice published herein do not reflect or establish a standard of care and do not establish rules for the practice of medicine. The publication of this information is not intended as an offer to insure such conditions or exposures, or to indicate that MagMutual Insurance Company will underwrite such risks for the reader. Our liability is limited to the specific written terms and conditions of actual insurance policies issued.
I am an ACT funded clinical research fellow working with Dr David Jayne and the vasculitis group at Addenbrooke’s Hospital. My primary role has been working on the upcoming COMBIVAS trial: a small, experimental medicine study to examine the biological effects of combination therapy with rituximab (anti-CD20) and belimumab (anti-BLyS) in patients with ANCA-associated vasculitis. This study is funded through the MRC/EMINENT programme: a novel collaboration between GSK and 5 major research centres in the UK, including Cambridge University. Through this post I have benefited from training in laboratory techniques and experimental medicine study conduct. We are working closely with GSK in the set up this trial which has given me great insight into the academic-industry interface and the benefits of this collaborative approach to medical research. I am planning to use trial data and concepts behind the trial to form the basis of my PhD thesis.